Redalpine Capital I Exits InSphero

redalpineZurich, Switzerland-based Redalpine Capital I exited InSphero, a developer of organotypic 3D cell cultures for in-vitro testing, at a double-digit multiple. 

The Schlieren-based company recently closed a CHF 20m Series C funding round with the family investment office of a globally active entrepreneur represented through HP Wild Holding AG.

Dr. Jan Lichtenberg, CEO and co-founder, InSphero currently counts most of the leading pharmaceutical, chemical and cosmetics companies among its customers and has received awards for its scientific and commercial achievements. Last year, it was recognised as the most promising and innovative startup in Switzerland. 




Join the discussion